A multicultural group practicing yoga together in a bright studio

Embody vs Oak: GLP-1 Comparison 2026

Embody vs Oak: pricing, medication type, clinical support, and which mid-market GLP-1 patient each program fits. Both programs’ prices verified July 2026 or later; each price carries its own date in the table below.

By RangeYourselfUpdated August 21, 20264 min read

Quick answer

Embody and Oak both offer GLP-1 telehealth, but they package medication, support, and pricing differently. The right choice depends on whether you weight cost, clinical touch, or formulation flexibility highest.

Side-by-side comparison

Feature	Embody	Oak
Best for	Personalized compounded blends and hands-on support	Compounded GLP-1 shoppers comparing cash-pay options
Medication type	Compounded GLP-1 with personalization	Compounded semaglutide and tirzepatide, injectable and sublingual (Oak Longevity)
Pricing model	Monthly subscription, formulation-tiered	Cash-pay subscription; recurring price not consistently listed publicly (advertised $119–$190/mo under promos)
Semaglutide price	Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.)	Compounded, advertised from $119/mo (promo); recurring rate not consistently listed, confirm in enrollment
Tirzepatide price	Compounded tirzepatide / GLP-1+GIP, $119/mo (flat pricing shown on the verified offer page), verified 2026-08-21; no 'was' comparison price shown for tirzepatide specifically, confirm at signup.	Compounded, advertised from $185/mo (promo); recurring rate not consistently listed, confirm in enrollment
Key watchout	Embody's published price is a live time-limited promo with no confirmed standing rate: it changed intra-day on 2026-07-14 ($99/mo AM, '$200 OFF, was $299', to $149/mo PM, '$150 OFF, was $299'), and by 2026-08-21 the same offer URL had dropped further to a new low. We rank it at its current verified purchasable price ($69/mo semaglutide) and label it a promo, confirm the exact cost at checkout. Custom blends also warrant scrutiny on ingredient transparency.	Oak advertises figures from $119 to $190/mo across its own pages under promotions and does not list one consistent recurring price, confirm the exact ongoing rate in the enrollment flow before subscribing. Fees are non-refundable once charged.
Price checked	Checked by a person August 21, 2026 · an automated check re-read it September 3, 2026	Checked by a person July 12, 2026

When to choose Embody

You want a compounded program that personalizes the formulation
You're comfortable evaluating ingredient lists and provider transparency
You'd value bundled adjuncts (anti-nausea, B12, etc.) when offered
You're escalating dose and want a provider that adjusts with you

Check current Embody pricing →

When to choose Oak

You want compounded semaglutide or tirzepatide (injectable or sublingual) on a cash-pay plan
You're comfortable confirming the exact recurring price in Oak's enrollment flow rather than on the public site
You prefer async care with no video visit required
You want same-day provider review and free shipping

Check current Oak pricing →

Full reviews

Frequently asked questions

Is Embody cheaper than Oak?

Neither Embody nor Oak is uniformly cheaper, both publish dose-banded and formulation-banded pricing that depends on the exact product, dose, and any insurance pathway. Compare the specific tier you'd be on at each before deciding.

Which is better for semaglutide or tirzepatide, Embody or Oak?

Both Embody and Oak prescribe semaglutide and tirzepatide where appropriate. Choose based on how each program handles your target medication, not just the entry price.

Are Embody and Oak compounded or brand-name?

Embody offers compounded glp-1 with personalization. Oak offers compounded semaglutide and tirzepatide, injectable and sublingual (oak longevity). If you specifically want brand-name Wegovy or Zepbound, lean toward whichever explicitly supports brand access; if compounded is fine, both can typically meet that need.

Can I switch from Embody to Oak?

Yes, switching between Embody and Oak is straightforward in most states. You typically finish your current month, complete a new intake with the other provider, and they handle the prescription. Watch for overlap on auto-renewal billing and confirm any dose-tier or formulation differences with the new clinician before your next shipment.

Compare Embody and Oak to other programs

Alert me when this gets cheaper

These prices move. Get one email when we publish a verified price drop, the programs on this list included. No spam. Unsubscribe any time.

Related guides

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers, verified on the dates shown in the table above, and may change. Numbers like Compounded, $69/mo (limited-time promo, was $299), verified 2026-08-21; confirm current price at checkout. Standard/recurring price not publicly listed. (Same offer showed $99/mo and $149/mo promos on 2026-07-14, see price history.) and Compounded, advertised from $119/mo (promo); recurring rate not consistently listed, confirm in enrollment are starting tiers, not your guaranteed long-term cost.